Product
Veliparib
Aliases
ABT-888, PARP-1 inhibitor ABT-888, Veliparib Placebo
Name
veliparib
Target
Schlafen-11 (SLFN11)
FDA Approved
No
Ema approved
Status
0
21 clinical trials
1 drug
1 abstract
83 indications
Indication
Breast CancerIndication
Ovarian CancerIndication
Ovarian CarcinomaIndication
Non-Hodgkin LymphomaIndication
Stage IV Non-Hodgkin LymphomaIndication
Solid TumorIndication
Malignant Solid NeoplasmIndication
Malignant NeoplasmIndication
Acute Myeloid LeukemiaIndication
Atypical chronic myeloid leukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
Essential ThrombocythemiaIndication
MyelofibrosisIndication
Polycythemia VeraIndication
Recurrent Acute Myeloid LeukemiaIndication
Carcinoma of Unknown PrimaryIndication
Endometrial CancerIndication
Esophageal cancerIndication
Liver FailureIndication
Lung CancerIndication
Head and Neck CancerIndication
Testicular CancerIndication
MelanomaIndication
Metastatic Malignant NeoplasmIndication
Kidney FailureIndication
Bladder CancerIndication
Pancreatic CancerIndication
Stage IV Pancreatic CancerIndication
Anaplastic AstrocytomaIndication
GlioblastomaIndication
Malignant GliomaIndication
Acute Lymphoblastic LeukemiaIndication
Acute lymphoblastic leukemia, adult typeIndication
Adult T Acute Lymphoblastic LeukemiaIndication
Adult Acute Lymphoblastic LeukemiaIndication
Adult Acute Myeloid LeukemiaIndication
Rectal AdenocarcinomaIndication
Rectal CancerIndication
Metastatic Malignant Solid NeoplasmIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
NeoplasmIndication
Adenocarcinoma of the LungIndication
Mixed SubtypeIndication
Lung Large Cell CarcinomaIndication
squamous cell carcinoma of the lungIndication
Lung AdenocarcinomaIndication
Stage III Lung Non-Small Cell CancerIndication
Stage IIIA Lung Non-Small Cell CancerIndication
GliosarcomaIndication
Hodgkin lymphomaIndication
Non-Hodgkin lymphomaIndication
Stage III Breast CancerIndication
Colon CancerIndication
Stage III Pancreatic CancerIndication
Stage IIIA Breast CancerIndication
Stage IIIA Colon CancerIndication
Ovarian Cancer AJCC Stage IIIA v6 and v7Indication
Breast cancerIndication
Stage IV Lung CancerIndication
Stage IV Colon Cancer AJCC v7Indication
Triple-Negative Breast CarcinomaIndication
Breast Cancer, Stage IVIndication
Breast CarcinomaIndication
Large Cell Lung CarcinomaIndication
Neuroendocrine CarcinomaIndication
Small Cell Lung CancerIndication
Stage IV Non-Small Cell Lung CancerDrug
VeliparibIndication
CancerIndication
Aggressive Non-Hodgkin LymphomaIndication
Solid NeoplasmIndication
Mantle Cell LymphomaIndication
T-Cell Non-Hodgkin LymphomaClinical trial
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast CancerStatus: Completed, Estimated PCD: 2019-04-05
Clinical trial
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Terminated, Estimated PCD: 2019-05-03
Abstract
SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).Org: University of Virginia, Charlottesville, VA, USA, Fred Hutchinson Cancer Research Center, Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Levine Cancer Institute,
Clinical trial
A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2021-09-03
Clinical trial
A Phase I Study of a Combination of MM-398 and Veliparib in Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2021-06-19
Clinical trial
NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)Status: Active (not recruiting), Estimated PCD: 2023-05-31
Clinical trial
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2017-11-10
Clinical trial
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic CancerStatus: Active (not recruiting), Estimated PCD: 2019-05-01
Clinical trial
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 MutationsStatus: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute LeukemiasStatus: Active (not recruiting), Estimated PCD: 2014-03-21
Clinical trial
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal CancerStatus: Completed, Estimated PCD: 2020-04-21
Clinical trial
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2019-01-13
Clinical trial
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)Status: Active (not recruiting), Estimated PCD: 2019-05-26
Clinical trial
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter HypermethylationStatus: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
Phase I Trial of Low-Dose Cyclophosphamide in Combination With Veliparib (ABT-888) in HER2/Neu-Negative Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2016-11-25
Clinical trial
Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung CancerStatus: Completed, Estimated PCD: 2016-12-08
Clinical trial
Pre-Operative PARPi and Irradiation (POPI) in Women With an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast CancerStatus: Completed, Estimated PCD: 2023-09-06
Clinical trial
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair GenesStatus: Completed, Estimated PCD: 2018-03-11